Abstract | PURPOSE: EXPERIMENTAL DESIGN:
Rituximab-resistant cell lines and primary CLL cells were used to investigate the antitumor efficacy of the combination of rILYd4 with ofatumumab or rituximab. Propidium iodide staining or alamarBlue assay were used to evaluate the CDC effect. The levels of CD20 and CD59 on the cell membrane were analyzed by flow cytometry. RESULTS: rILYd4 enhanced CDC effects mediated by ofatumumab or rituximab on rituximab-resistant lymphoma cells and primary CLL cells in vitro. The sensitivity to CDC effects mediated by ofatumumab positively correlated with the ratio of CD20/CD59 and negatively correlated with CD59 levels on CLL cells. The degree to which rILYd4 enhanced CDC correlated positively with the CD59 levels on CLL cells. CONCLUSIONS:
|
Authors | Xiaowen Ge, Lin Wu, Weiguo Hu, Stacey Fernandes, Chun Wang, Xu Li, Jennifer R Brown, Xuebin Qin |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 17
Issue 21
Pg. 6702-11
(Nov 01 2011)
ISSN: 1557-3265 [Electronic] United States |
PMID | 21918174
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2011 AACR |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Bacteriocins
- CD59 Antigens
- Peptide Fragments
- intermedilysin protein, Streptococcus intermedius
- CD59 protein, human
- Rituximab
- Complement System Proteins
- ofatumumab
|
Topics |
- Antibodies, Monoclonal
(administration & dosage, pharmacology)
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Bacteriocins
(administration & dosage, pharmacology)
- CD59 Antigens
(immunology, metabolism)
- Cell Line, Tumor
- Complement System Proteins
(immunology)
- Cytotoxicity, Immunologic
(drug effects)
- Drug Synergism
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy, immunology)
- Lymphoma, B-Cell
(drug therapy, immunology)
- Peptide Fragments
(administration & dosage)
- Protein Structure, Tertiary
- Rituximab
|